INO Inovio Pharmaceuticals, Inc.
$0.94▲ +5.44%
Healthcare
Other
Volume 320.8K
Avg Volume (10D) 4.76M
Key Metrics & Fundamentals
Market Cap
$97.03M
P/E Ratio
–
Div Yield
0.00%
52W Range
0.56 - 2.72
% vs 50 MA
-23.80%
% vs 200 MA
-30.24%
RSI-14
38.3
MACD Histogram
-0.0200
Beta (1Y vs SPY)
0.38
Free Cash Flow
-$18.05M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$31.82M
COGS
–
Operating Exp
$18.62M
Operating Income
-$18.62M
EBIT
-$18.62M
Pretax Income
-$6.01M
Net Income
-$6.01M
EPS (Diluted)
-0.07
Price & Volume History
Loading chart…
Recent News
Inovio Says it Secured Favorable Judgment in VGXI, GeneOne Litigation
MT Newswires · Oct 20, 2026 5:44 PM ET
FDA Backs PFE's Tukysa Combo in Front-Line Maintenance Breast Cancer
Zacks · Oct 8, 2026 10:45 AM ET
PGEN Stock Up More Than 50% in 3 Months: Here's What You Should Know
Zacks · Oct 5, 2026 10:44 AM ET
PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?
Zacks · Sep 30, 2026 11:08 AM ET
Can PGEN's AdenoVerse Pipeline Create Growth Beyond Papzimeos?
Zacks · Sep 24, 2026 10:17 AM ET
Precigen Gains 43% in 3 Months: Is It an Indication to Buy the Stock?
Zacks · Sep 14, 2026 10:12 AM ET
Inovio Nears FDA Decision on INO-3107 as Oct. 30 PDUFA Date Looms
MarketBeat · Sep 11, 2026 9:02 AM ET
Can Papzimeos Drive Precigen's Growth Through the Rest of 2026?
Zacks · Sep 10, 2026 11:03 AM ET
Inovio Pharmaceuticals Nears Oct. 30 FDA Decision for INO-3107 in RRP
MarketBeat · Sep 10, 2026 7:02 AM ET
INOVIO to Participate in Upcoming Investor Conferences
PR Newswire · Sep 1, 2026 4:05 PM ET
Financial Overview - Income Statement
Quarterly
Mar 2025
See INO's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.